Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel - Bio-Synectics

Next Previous
Drug Profile

Docetaxel - Bio-Synectics

Alternative Names: BS-102; Docetaxel trihydrate - Bio-Synectics

Latest Information Update: 28 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Synectics
  • Developer Bio-Synectics; Nanotechnology Characterization Lab
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for preclinical development in Cancer in South Korea (IV, Powder)
  • 17 Jan 2022 Preclinical trials in Cancer in USA (IV) (Bio-Synectics pipeline, January 2022)
  • 07 Oct 2019 BS 102 is available for licensing as of 07 Oct 2019. http://www.bio-synectics.com/new/eng/company1.php

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top